Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4

Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4

The hepatitis C virus (HCV) genotype is an important predictive outcome parameter for pegylated interferon plus ribavirin therapy. Most published therapeutic trials to date have enrolled mainly patients with HCV genotypes 1, 2 and 3. Limited studies have focused on genotype 4 patients, who have had...

Full description

Bibliographic Details
Main Authors: Juan José Urquijo, Moisés Diago, M.D., Jaume Boadas, Ramón Planas, Ricard Solá, Juan Angel del Olmo, Javier Crespo, José Carlos Erdozaín, María Dolores Antón, Carlos Arocena, Dolores Suarez, Josep Giné, Josep M Barrera, Javier Gracia-Samaniego, Ricardo Perez, Blai Dalmau, Miguel Montoro
Format: Article
Language:English
Published: Elsevier 2013-01-01
Series:Annals of Hepatology
Subjects:
Peginterferon
Ribavirin
Sustained viral response
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268119313821

Internet

http://www.sciencedirect.com/science/article/pii/S1665268119313821

Similar Items